Trial Profile

A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Treatment of Metabolic Abnormalities in Patients With Familial Partial Lipodystrophy

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 02 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mibavademab (Primary) ; Mibavademab (Primary)
Indications Congenital generalised lipodystrophy
Focus Therapeutic Use
Acronyms LEAP
Sponsors Regeneron Pharmaceuticals

Most Recent Events

04 Jun 2024 Status changed from completed to discontinued.(Reason the study was stopped: Sponsor Decision)
02 May 2024 Status changed from active, no longer recruiting to completed.
13 Mar 2024 This trial has been discontinued in Spain, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com